No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival

The prognostic improvement attributed to genetic markers over current prognostic system has not been well studied for melanoma. The goal of this study is to evaluate the added prognostic value of Vitamin D Pathway (VitD) SNPs to currently known clinical and demographic factors such as age, sex, Breslow thickness, mitosis and ulceration (CDF). We utilized two large independent well-characterized melanoma studies: the Genes, Environment, and Melanoma (GEM) and MD Anderson studies, and performed variable selection of VitD pathway SNPs and CDF using Random Survival Forest (RSF) method in addition to Cox proportional hazards models. The Harrell’s C-index was used to compare the performance of model predictability. The population-based GEM study enrolled 3,578 incident cases of cutaneous melanoma (CM), and the hospital-based MD Anderson study consisted of 1,804 CM patients. Including both VitD SNPs and CDF yielded C-index of 0.85, which provided slight but not significant improvement by CDF alone (C-index = 0.83) in the GEM study. Similar results were observed in the independent MD Anderson study (C-index = 0.84 and 0.83, respectively). The Cox model identified no significant associations after adjusting for multiplicity. Our results do not support clinically significant prognostic improvements attributable to VitD pathway SNPs over current prognostic system for melanoma survival.

[1]  A. Jetten,et al.  Endogenously produced nonclassical vitamin D hydroxy-metabolites act as “biased” agonists on VDR and inverse agonists on RORα and RORγ , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  David A. Jolliffe,et al.  Single nucleotide polymorphisms in the vitamin D pathway associating with circulating concentrations of vitamin D metabolites and non-skeletal health outcomes: Review of genetic association studies , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  A. Jetten,et al.  RORα and RORγ expression inversely correlates with human melanoma progression , 2016, Oncotarget.

[4]  Hongliang Liu,et al.  Genetic variants in the vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease‐specific survival , 2016, Pigment cell & melanoma research.

[5]  T. Kirchhoff,et al.  The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis , 2016, Clinical Cancer Research.

[6]  Wei Li,et al.  Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland , 2015, Scientific Reports.

[7]  Yuan-Ting Zhang,et al.  Risk Prediction of One-Year Mortality in Patients with Cardiac Arrhythmias Using Random Survival Forest , 2015, Comput. Math. Methods Medicine.

[8]  Jin Wang,et al.  Novel activities of CYP11A1 and their potential physiological significance , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  R. Lucas,et al.  Vitamin D Deficiency at Melanoma Diagnosis Is Associated with Higher Breslow Thickness , 2015, PloS one.

[10]  S. Rosso,et al.  Sun Exposure and Melanoma Survival: A GEM Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[11]  D. Polsky,et al.  Development of a Melanoma Risk Prediction Model Incorporating MC1R Genotype and Indoor Tanning Exposure: Impact of Mole Phenotype on Model Performance , 2014, PloS one.

[12]  Jin Wang,et al.  RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20‐hydroxy‐ and 20,23‐dihydroxyvitamin D , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  E. Giovannucci,et al.  The role of vitamin D in reducing cancer risk and progression , 2014, Nature Reviews Cancer.

[14]  T. Kirchhoff,et al.  Melanoma risk loci as determinants of melanoma recurrence and survival , 2013, Journal of Translational Medicine.

[15]  J. Barrett,et al.  MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study , 2013, BMC Cancer.

[16]  A. Brożyna,et al.  Expression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression. , 2013, Human pathology.

[17]  Wei Li,et al.  In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1 , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  R. Millikan,et al.  Vitamin D receptor polymorphisms in patients with cutaneous melanoma , 2012, International journal of cancer.

[19]  Caitlin P. McHugh,et al.  Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. , 2011, Human molecular genetics.

[20]  A. Brożyna,et al.  Expression of vitamin D receptor decreases during progression of pigmented skin lesions. , 2011, Human pathology.

[21]  L. Keele,et al.  A General Approach to Causal Mediation Analysis , 2010, Psychological methods.

[22]  Udaya B. Kogalur,et al.  High-Dimensional Variable Selection for Survival Data , 2010 .

[23]  L. Keele,et al.  Identification, Inference and Sensitivity Analysis for Causal Mediation Effects , 2010, 1011.1079.

[24]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Barrett,et al.  Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Hemant Ishwaran,et al.  Random Survival Forests , 2008, Wiley StatsRef: Statistics Reference Online.

[27]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[28]  R. Millikan,et al.  A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. , 2006, International journal of epidemiology.

[29]  T. Dwyer,et al.  Does the addition of information on genotype improve prediction of the risk of melanoma and nonmelanoma skin cancer beyond that obtained from skin phenotype? , 2004, American journal of epidemiology.

[30]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[31]  S. Rosso,et al.  Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: A population-based study. , 2015, Carcinogenesis.

[32]  Iris E. Dumenden.  The Research Assistant , 2012 .

[33]  G. Abecasis,et al.  Genotype imputation. , 2009, Annual review of genomics and human genetics.

[34]  L. Breiman.  Random Forests , 2001, Machine Learning.

[35]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[36]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.